DiaMedica Therapeutics Inc. (F2KA.F)
| Previous close | 3.2400 |
| Open | 3.0600 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 3.0600 - 3.2400 |
| 52-week range | 2.5400 - 10.5000 |
| Volume | |
| Avg. volume | 202 |
| Market cap | 62.732M |
| Beta (5Y monthly) | 1.75 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.5650 |
| Earnings date | 12 Aug 2024 - 16 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireDiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results
MINNEAPOLIS, May 08, 2024--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the quarter ended March 31, 2024. Management will host a conference call Thursday, May 9, 2024 at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and first quarter 2024 financial results.
- Business Wire
DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024
MINNEAPOLIS, May 02, 2024--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its first quarter 2024 financial results will be released after the markets close on Wednesday, May 8th. DiaMedica will host a live conference call on Thursday, May 9th at 7:00 AM Central Time to provide a business update and discuss financial results.
Simply Wall St.Bullish DiaMedica Therapeutics Insiders Loaded Up On US$15.7m Of Stock
Multiple insiders secured a larger position in DiaMedica Therapeutics Inc. ( NASDAQ:DMAC ) shares over the last 12...
